An insight into pharmacological and clinical basis of anti-IgE for add-on therapy of severe asthma
Shortness of Breath · 2013
DOI: 10.11138/sob/2013.2.4.176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Shortness of Breath, 2013. Verfasst von Girolamo Pelaia.
Abstract (Originalsprache)
IgE antibodies are crucially involved in mediating, \nmaintaining and amplifying the allergic cascade. The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Anti-IgE inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of \ndown-regulating the expression of high affinity IgE \nreceptors on inflammatory cells, as well as the numbers \nof eosinophils in both peripheral blood and induced sputum. Randomized clinical trials showed relevant clinical effects of omalizumab including improvements of respiratory symptoms and quality of life. Moreover, a marked reduction of asthma exacerbations, emergency room visits, and use of \nsystemic corticosteroids and rescue bronchodilators was also observed. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for most severe patients with persistent allergic asthma, \ninadequately controlled by high doses of standard treatments.
Zitieren
APA
Pelaia, G. (2013). An insight into pharmacological and clinical basis of anti-IgE for add-on therapy of severe asthma. Shortness of Breath. https://doi.org/10.11138/sob/2013.2.4.176
Vancouver
Pelaia G. An insight into pharmacological and clinical basis of anti-IgE for add-on therapy of severe asthma. Shortness of Breath. 2013. doi:10.11138/sob/2013.2.4.176
BibTeX
@article{Pelaia2013,
author = {Pelaia, Girolamo},
title = {An insight into pharmacological and clinical basis of anti-IgE for add-on therapy of severe asthma},
journal = {Shortness of Breath},
year = {2013},
doi = {10.11138/sob/2013.2.4.176}
}
EUVIMED